Coastlands Capital LP purchased $9K of ADIL (indirect holdings)
Coastlands Capital LP purchased 3,233 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at an average of $2.69 ($2.65–$2.75) across 2 trades over 2026-07-14 to 2026-07-16.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market purchase by a 10% owner (indirect) across two dates and the post-transaction share count.
Market read
Traders may treat this as a minor sentiment input, but it does not provide new clinical, regulatory, or financial information.
What to watch
No 10b5-1 plan is cited, but the filing does not explain intent, timing rationale, or whether other insiders are selling/buying concurrently.
Background
The article is an SEC Form 4 insider transaction disclosure for ADIAL PHARMACEUTICALS, INC. (ADIL).
Ticker impact
Coastlands Capital LP, a 10% owner, bought 3,233 ADIL shares in two open-market trades at $2.6500 to $2.7500 (indirect).
Low near-term impact; any effect is likely limited to sentiment/flow rather than a fundamental repricing.
Form 4 confirms insider ownership activity, but the disclosed dollar value (~$8.7k) is small and there is no accompanying operational or financial catalyst in the filing.
Market effects
No sector-level implications; this is a single-company ownership transaction.
None indicated.
None indicated.
Counterpoint
The purchase is indirect and small in dollar terms, so it may reflect routine rebalancing or administrative effects rather than a strong bullish signal.
Key entities
- issuerADIAL PHARMACEUTICALS, INC.
Subject of the Form 4 insider transaction disclosure.
- 10% ownerCoastlands Capital LP
Reporter of the indirect open-market purchase of ADIL shares.
